Monitoring of IFN- gamma level in Pfizer/BioNTech vaccinated Iraqi's people
Journal of Pharmaceutical Negative Results
; 13(4):612-616, 2022.
Article
in English
| EMBASE | ID: covidwho-2206675
ABSTRACT
Background:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. The most reliable approach to stop the spread of infectious illnesses is through vaccination. Safe and effective vaccines are needed urgently. Method(s) The study had eighty-one (81) participants ranging from 18 to 66 years old who were recently injected with COVID-19 mRNA Pfizer/BioNTech [BNT162b2] vaccines. They received two vaccine doses of 30 microg, 0.3 mL injections twenty-one (21) days apart. Before the first vaccination, blood samples were collected. This procedure was repeated on days 7-10 following the first immunization, and on 7-10 days following the second dosage. All samples were tested for IFN-gamma using a High Sensitivity Human ELISA Kit corresponding to each marker (Elabscience/United State). Result(s) Compared to before vaccination and the first dosage, IFN-g levels were higher after the second dose. Conclusion(s) Our study demonstrated that vaccinations caused Th1 biases in all groups. Copyright © 2022 Wolters Kluwer Medknow Publications. All rights reserved.
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Topics:
Vaccines
Language:
English
Journal:
Journal of Pharmaceutical Negative Results
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS